Bvf Inc Buys Ironwood Pharmaceuticals Inc, Merus NV, Xencor Inc, Sells Array BioPharma Inc, CytomX Therapeutics Inc, AnaptysBio Inc

• New Purchases: IRWD, MRUS, XNCR, RCUS, ADRO, ALBO, GNCA, EPIX,
• Added Positions: CRVS, IMDZ, PIRS, FWP, VSTM, PTGX, SPRO, SBPH,
• Reduced Positions: ARRY, ANAB, BPMC, XENE, GTXI, CTIC, CCXI, SNSS, CNCE, TOCA,
• Sold Out: CTMX, CASC, GLYC, ACHN, ITCI, ANTH, PTIE,

For the details of BVF INC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=BVF+INC

1. ChemoCentryx Inc (CCXI) - 7,201,316 shares, 9.93% of the total portfolio. Shares reduced by 5.09%
2. Ironwood Pharmaceuticals Inc (IRWD) - 5,542,400 shares, 8.67% of the total portfolio. New Position
3. Array BioPharma Inc (ARRY) - 5,062,768 shares, 8.38% of the total portfolio. Shares reduced by 41.72%
4. Blueprint Medicines Corp (BPMC) - 655,611 shares, 6.09% of the total portfolio. Shares reduced by 14.56%
5. Arqule Inc (ARQL) - 16,436,912 shares, 4.8% of the total portfolio.

Bvf Inc initiated holding in Ironwood Pharmaceuticals Inc. The purchase prices were between $13.29 and $16.28, with an estimated average price of $14.88. The stock is now traded at around $17.97. The impact to a portfolio due to this purchase was 8.67%. The holding were 5,542,400 shares as of 2018-03-31.

Bvf Inc initiated holding in Merus NV. The purchase prices were between $16.07 and $19.87, with an estimated average price of $18.14. The stock is now traded at around $17.29. The impact to a portfolio due to this purchase was 4.54%. The holding were 2,419,443 shares as of 2018-03-31.

Bvf Inc initiated holding in Xencor Inc. The purchase prices were between $21.18 and $33.78, with an estimated average price of $26.15. The stock is now traded at around $30.84. The impact to a portfolio due to this purchase was 2.74%. The holding were 902,000 shares as of 2018-03-31.

Bvf Inc initiated holding in Arcus Biosciences Inc. The purchase prices were between $15.44 and $17.71, with an estimated average price of $16.66. The stock is now traded at around $16.37. The impact to a portfolio due to this purchase was 1.99%. The holding were 1,269,788 shares as of 2018-03-31.

Bvf Inc initiated holding in Aduro Biotech Inc. The purchase prices were between $6 and $9.3, with an estimated average price of $7.3. The stock is now traded at around $7.65. The impact to a portfolio due to this purchase was 0.76%. The holding were 806,534 shares as of 2018-03-31.

Bvf Inc initiated holding in Albireo Pharma Inc. The purchase prices were between $26.78 and $39.35, with an estimated average price of $33.67. The stock is now traded at around $28.90. The impact to a portfolio due to this purchase was 0.74%. The holding were 225,000 shares as of 2018-03-31.

Bvf Inc added to a holding in Corvus Pharmaceuticals Inc by 325.40%. The purchase prices were between $7.48 and $11.53, with an estimated average price of $9.46. The stock is now traded at around $9.65. The impact to a portfolio due to this purchase was 1.74%. The holding were 1,954,254 shares as of 2018-03-31.

Bvf Inc added to a holding in Immune Design Corp by 179.37%. The purchase prices were between $2.9 and $4.2, with an estimated average price of $3.54. The stock is now traded at around $3.65. The impact to a portfolio due to this purchase was 0.88%. The holding were 4,106,200 shares as of 2018-03-31.

Bvf Inc added to a holding in Pieris Pharmaceuticals Inc by 36.93%. The purchase prices were between $6.8 and $9.45, with an estimated average price of $7.74. The stock is now traded at around $5.93. The impact to a portfolio due to this purchase was 0.67%. The holding were 3,592,549 shares as of 2018-03-31.

Bvf Inc added to a holding in Forward Pharma A/S by 37.63%. The purchase prices were between $2.17 and $5.36, with an estimated average price of $3.48. The stock is now traded at around $2.28. The impact to a portfolio due to this purchase was 0.29%. The holding were 4,755,117 shares as of 2018-03-31.

Bvf Inc added to a holding in Verastem Inc by 21.64%. The purchase prices were between $2.92 and $3.81, with an estimated average price of $3.23. The stock is now traded at around $4.07. The impact to a portfolio due to this purchase was 0.15%. The holding were 2,737,000 shares as of 2018-03-31.

Bvf Inc added to a holding in Protagonist Therapeutics Inc by 37.90%. The purchase prices were between $8.46 and $23.08, with an estimated average price of $18.86. The stock is now traded at around $8.42. The impact to a portfolio due to this purchase was 0.1%. The holding were 405,600 shares as of 2018-03-31.

Bvf Inc sold out a holding in CytomX Therapeutics Inc. The sale prices were between $21.11 and $34.22, with an estimated average price of $28.36.

Bvf Inc sold out a holding in Cascadian Therapeutics Inc. The sale prices were between $3.56 and $10.06, with an estimated average price of $7.81.

Bvf Inc sold out a holding in GlycoMimetics Inc. The sale prices were between $16.06 and $25.35, with an estimated average price of $20.8.

Bvf Inc sold out a holding in Achillion Pharmaceuticals Inc. The sale prices were between $2.65 and $4.23, with an estimated average price of $3.27.

Bvf Inc sold out a holding in Intra-Cellular Therapies Inc. The sale prices were between $15.16 and $25.49, with an estimated average price of $19.48.

Bvf Inc sold out a holding in Anthera Pharmaceuticals Inc. The sale prices were between $0.31 and $2.7, with an estimated average price of $1.49.